Janssen

Janssen, PATH collaborate for Rilpivirine

Wednesday, September 25, 2013 12:21 PM

Janssen R&D Ireland has signed a license agreement with PATH for the early development of the human immunodeficiency virus type 1 (HIV-1) medicine rilpivirine in a long-acting injection (depot formulation) as potential pre-exposure prophylaxis (PrEP) against HIV infection.

More... »

Otsuka to acquire Astex Pharmaceuticals

Friday, September 6, 2013 03:00 PM

Otsuka Pharmaceuticals will acquire Astex Pharmaceuticals for approximately $886 million, through a tender offer for all outstanding Astex shares expected to close in the fourth quarter.

More... »

Wellcome Trust, KU Leuven, Janssen collaborate

Wednesday, September 4, 2013 11:53 AM

Wellcome Trust, Janssen and KU Leuven are collaborating for dengue antiviral drugs. The collaboration will build on an existing three-year drug discovery program at the Rega Institute and the Center for Drug Design and Discovery (CD3) at KU Leuven, supported by a Wellcome Trust Seeding Drug Discovery Award.

More... »

Roche, Chugai’s schizophrenia drug forecast to earn $1.5b in 2022

Wednesday, August 28, 2013 12:43 PM

Decision Resources, a research and advisory firms for pharmaceutical and healthcare issues, has found Roche/Chugai’s glycine transporter-1 inhibitor bitopertin is poised to be the first approved treatment to address negative symptoms in schizophrenia following its forecasted launch in the U.S. and Europe in 2016 and in Japan in 2017. As a first-in-class agent for the treatment of these prominent yet underserved symptoms of schizophrenia, Decision Resources expects bitopertin will garner nearly $1.5 billion in major-market sales in 2022.

More... »

Anti-TNF infusion therapy approved for RA patients

Friday, July 19, 2013 01:20 PM

The FDA has approved Janssen Biotech’s Simponi Aria (golimumab) infusion for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) in combination with methotrexate. Simponi Aria, the only fully-human anti-tumor necrosis factor (TNF)-alpha infusible therapy, has been shown to improve signs, symptoms and physical function and inhibit the progression of structural damage.

More... »

Janssen, J&J Innovation ally with The Icahn School Of Medicine at Mount Sinai

Wednesday, July 3, 2013 12:30 PM

Janssen Biotech and Johnson & Johnson Innovation have established a research alliance with The Icahn School of Medicine at Mount Sinai to advance the scientific understanding of inflammatory bowel disease (IBD) and the discovery of next generation therapeutic solutions.

More... »

J&J pharma segment poised with over 10 potential new product filings by 2017

Friday, May 24, 2013 01:28 PM

At a meeting with industry analysts, senior leaders from the Janssen Pharmaceutical companies of Johnson & Johnson announced they anticipate submitting more than 10 new product filings and more than 25 significant brand line extensions by 2017.

More... »

Janssen Biotech’s Simponi receives FDA approval for ulcerative colitis

Monday, May 20, 2013 08:00 AM

The FDA has approved Janssen Biotech’s Simponi (golimumab) for the treatment of moderately to severely active ulcerative colitis (UC) in adult patients who have demonstrated corticosteroid dependence or who have had an inadequate response to or failed to tolerate oral aminosalicylates, oral corticosteroids, azathioprine, or 6-mercaptopurine.

More... »

FDA approves Janssen’s Invokana for type 2 diabetes

Monday, April 1, 2013 02:15 PM

The FDA has approved Janssen Pharmaceuticals’ Invokana (canagliflozin) for the treatment of adults with type 2 diabetes.

More... »

Janssen launches global cardiovascular research program, five new studies

Friday, March 8, 2013 10:47 AM

Janssen Research & Development has launched EXPLORER, a comprehensive, global research program for XARELTO (rivaroxaban), an oral anticoagulant. The program includes studies that will evaluate XARELTO for investigational use in patients with chronic heart failure and in those with coronary artery disease or peripheral artery disease.

More... »